why choose us

First received: July 26, 2022

Clinical Trial: Evaluating Novel Therapies in ctDNA Positive GI Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Colon Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease

Brief Summary: This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial.The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocarcinomas) diagnosed with histologically confirmed GI cancers.These patients will have already completed all Standard of Care (SOC) treatments (including neoadjuvant, surgery, local therapies, and/or adjuvant therapy as applicable), as defined by the treating primary…

Read more